Nano-X Imaging Ltd. (NNOX) Q2 2026 Earnings Call Transcript

Good day and thank you for standing by. Welcome to the Nanox Q2 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star one one again. Please be advised that this conference is being recorded. I would now like to hand the conference over to your speaker today, Mike Cavanaugh, Investor Relations. Please go ahead.

Good morning and welcome to Nanox Imaging's second quarter 2026 investor call. Earlier today, Nanox Imaging Limited released financial results for the quarter ending June 30, 2026. The release is currently available on the investor section of the company's website. With me today are Erez Meltzer, Chief Executive Officer and Acting Chairman, and Guy Nathanson, Chief Financial Officer. Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements regarding the company's financial results, research and development, manufacturing, commercialization activities, regulatory process, and clinical activities, and other matters these statements are subject to risks uncertainties and assumptions that are based on management's current expectations as of today and may not be updated in the future therefore these statements should not be relied upon as representing the company's views as of any subsequent date factors that may cause such a difference include but are not limited to those described in the company's filings with the Securities and Exchange Commission. We'll also refer to certain non-GAAP financial measures to provide additional information to investors. A reconciliation of the non-GAAP to GAAP measures is provided with our press release, which reconciles the following non-GAAP measures to the closest equivalent figures under GAAP. non-GAAP gross margin, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP net loss, and adjusted EBITDA loss. With that, I'd now like to turn the call over to Erez Meltzer.

Thank you all for joining us today in the two months since our last call we have advanced commercialization across several areas of the business our management team has completed a thorough review of the business and started implementing lessons learned with progress reflected across our commercial operational and strategic priorities today i will focus on the steps we are taking to improve execution extend commercialization, and support the long-term value of the Nanox platform. While our business is trending in the right direction, as we discussed last quarter, our commercialization has taken longer than we expected when we initiated the commercial phase. We have already provided preliminary financial results last month, and our results are substantially consistent with those previously disclosed figures. The main friction points have been, as mentioned, operational. Commercialization requires close side-by-side coordination with small and medium-sized imaging centers, particularly around permitting, shielding, construction timelines, and integration into clinical workflows. These are practical deployment requirements, but they have been important lessons as we refine how we move systems from commercial agreement to active utilization. By identifying where the friction has occurred, we have been able to shape the changes we are now implementing. Most importantly, we are increasingly leveraging commercial partners with established relationship and workflow in the imaging space to meaningfully enhance our presence in the U.S. At the same time, our direct sales effort continues to support additional NanoXR CAPEX agreements and deployment activity, including the first NanoX Imaging Network installation in Philadelphia, which has already scanned its first patients. Beyond the U.S., we continue NanoXR deployment activity across Europe and Latin America, advance new NanoXAI commercial and pilot programs in India and the U.S., and move forward with the restructuring of our South Korea operations to better align resources with our core technologies and commercialization priorities. We continue to broaden our U.S. footprint through strategic collaborations, customers' evaluations, and deployment activities, including our recently announced collaboration with RodNet and ongoing work with leading clinical institutions with the goal of expanding our engagement with healthcare chains and increasing activity within those chains. As we disclosed in our last call, the NanoXARG system has been operational for several months at RudNet sites. RudNet is the largest outpatient imaging center operator in the United States and has deployed the NanoXARG system at one of its facilities, where it is now in commercial use and integrated into routine clinical workflow. We continue to explore opportunities for clinical research, including early lung nodule detection. We believe this represents an important step in demonstrating NanoxArc's clinical value in a major outpatient imaging setting, and we are excited to continue this collaboration. We recently deployed a nano-SARC system through a capital equipment sale to an internationally recognized orthopedic center in Florida, which is part of an IDF, Integrated Delivery Network. As this organization integrates the system into its orthopedic imaging workflow, we are launching a strategic collaboration aimed at broadening the clinical use of Nanux Arc in orthopedics and generating clinical experience in a high-volume specialty care environment. We believe the true measure of innovation in medical imaging lies in clinical relevance and potential to improve patient care. Our continued engagement with leading healthcare organizations reflects our commitment to generating more real-world evidence and evaluating a growing number of clinical applications for our technology. For example, we recently installed an ARC system in an urgent care unit located in New Jersey. Turning to our commercial distribution partnership, we are seeing channel partners build pipelines activity that supports future CAPEX sales. In addition, our U.S.-based subsidiary, Nanox Impact Inc., has entered into a distribution agreement with Associated X-Ray Imaging Corp., a New England-based provider of medical imaging equipment and services, specializing in X-Ray, MRI, and CT system to support deployment of the Nanox Arc across the region. We now have 10 signed commercial distribution partnerships in the United States. Associated has already supported the customer installation of the Nano XR that is installed and operational, further demonstrating its ability to support deployment and service in the region. The agreement follows other recent engagements, including digital X-ray imaging, integrity medical services. elite surgical technologies. The goal is to supplement our direct sales force and increase our presence economically as we pursue broader coverage of major US markets. We're also expanding joint commercialization activity with our partners including participation in Howard's annual sales summit, our webinar our partnership with ROS and ongoing sales and marketing initiatives as more customers channel partners and physical gain first-hand experience with Nanook's art we are seeing encouraging utilization including sites performing hundreds of scans per month and one customer transitions from MSAS to capex purchase the house imaging network proof of concept is beginning to contribute to our commercialization strategy by targeting segments that may offer potentially higher reimbursement rates such as worker compensation groups and concierge medical providers through this initiative nanox completed the first nanox imaging network installation in philadelphia and the site has begun scanning its first patients. It is encouraging that we are already seeing reimbursement from insurers and payers with paid claims in the range of $200 to $700 per claim. This provides early validation of the commercial opportunity for the Nanox Imaging Network and support our focus on targeted CARES segments where reimbursement dynamics can be favorable. Based on the preliminary business model, we believe each site may have the potential to generate annual revenue in the range of half a million dollars to a million dollars, depending on utilization, reimbursement, payer mix, and site-level execution. In our rest-of-the-world markets, we advanced commercialization activities across Europe and Latin America. During the quarter, we completed an end-user deployment in the Czech Republic and advanced system deliveries in Romania and Greece through local distribution partners, which we have discussed on previous calls. We also appointed Solme RCSA as our new distribution partner in Costa Rica. further expanding our presence in Latin America. We also continue to develop commercial opportunities with distributors in Slovenia and Ecuador, and are preparing to ship a system to Argentina. Since the acquisition, our Teleradiology Services Division, USARAD, continued to deliver strong and consistent revenues during the first half of 2026, which grew on a year-over-year basis, averaging 14% growth driven by continued expansion of our teleragiology client base. USARAD Holdings, Inc. has once again earned the Joint Commission's gold seal of approval for ambulatory healthcare accreditation by demonstrating continuous compliance with its performance standards. The gold seal is a symbol of quality that reflects a healthcare organization's commitment to providing safe and quality patient care. We also extended U.S. ARAD engagement with a leading multinational aerospace organization. This renewal reflects the value of U.S. Arad services offering and our ability to support large organizations with reliable, high-quality teloradiology services. We continue to view the teloradiology business as both a source of recurring revenues and an important channel for advancing the commercialization of our broader imaging and AI solutions. NanoX AI advanced on both the commercial and the clinical fronts during the quarter. We recently announced that NanoX entered into an exclusive sales reseller agreement with Vertex Scientific Limited for the NanoX AI bone solution in the United Kingdom. Vertex is also the exclusive supplier of Hologic DXA scanners in the UK with an extensive network of keeping leaders, clinics, and hospitals. Moreover, we launched five new AI installations, pilots, across the United States and India. These engagements expand our clinical and commercial footprint and provide opportunities to demonstrate the value of our AI solution in real-world healthcare settings. We're actively supporting these organizations through the evaluation process and look forward to advancing discussion around broader deployments. We also completed a pilot study with Cedars-Sinai comparing Nanox AI Health AVC with standard of care tools for assessing aortic valve calcification. The study demonstrated greater than 92% agreement between the two approaches, reinforcing the accuracy of our technology and supporting its potential integration into existing imaging workflows. In addition, IRB approval has been received from a leading university-affiliated medical center for an upcoming clinical study, and we are now moving forward with data collection. To end my update on the AI business, I would like to share some reimbursement news. In the U.S., the Centers for Medicare and Medical Services establish a new healthcare common procedures coding system, code GO680, effective April 1, 2026, for algorithmic analysis of coronary artery calcium in or art-evolved calcification from chest CT scans. This creates a potential reimbursement pathway for the NanoX AI cardiac solution when used with eligible chest SCTA exams and when applicable there, documentation and medical necessity requirements are met. We view this as a positive development that may help support commercial adoption of NanoX AI by enabling providers to incorporate AI-driven analysis into existing imaging workflow. The new reimbursement code may expand the addressable market for the NanoX-i Cardioff solution by creating a direct reimbursement pathway for outpatient imaging centers and clinics performing eligible chest safety examinations. This pathway may enable qualifying providers to incorporate our cardio solution into existing CD workflows and receive reimbursement without requiring an additional imaging procedure. We are exploring further our engagement with two of our leading research sites, Mayer Medical Centers and Rabin Medical Center, by expanding our ongoing clinical work into rheumatology, an area we believe may represent a meaningful extension of the NANOX ARC value proposition. Together with these centers, we are evaluating the potential role of the AHRQ in the assessment and long-term management of chronic rheumatology conditions. While still in the research stage, we believe this work may help broaden our understanding of additional clinical applications for the AHRQ and inform future opportunities in rheumatology. I'd like to share a few additional updates on our OEM relationship and pursuits. Varex tubes are undergoing the final integration process to become our main X-ray tubes source for the NanoX Arc X system. We have additionally taken receipt of a Varex multi-beam X-ray vessel utilizing multiple NanoX emitters and have begun our initial testing. We are excited to measure our amateurs' capabilities in this configuration and have potential partner interest in the areas of security, food inspection, and, of course, medical. Regarding Oak Ridge National Laboratory prototypes, we have completed and delivered prototypes of the latest design iteration to Oak Ridge for their assessment and integration with their intended application in security use cases. We're also pursuing discussions with other entities for this purpose. Overall, interest in the Nanox breakthrough source technology remains very strong. The NAS Health IT that we acquired at the end of 2025 has proven to be a valuable addition to Nanox and continue to contribute meaningful revenue in the first half of the year, supported by an expanding customer base and more than 20 new projects going live. As we complete our integration to make the business more scalable and begin to more fully leverage its synergies with Nanox AI, Nanox ARC, and US Rout business segments, we are very excited about the growth potential of this business. Turning to our South Korea operations, as we previously disclosed, we have been evaluating a range of strategic alternatives aimed at the optimizing our cost structure and maximizing the value of our asset in Korea. Following this review, we have decided to move forward with a broader structural transformation of our South Korea operation. As part of this process, we've idled our cheap production line and reduced our workforce in Korea by two-thirds. We are transitioning volume production activities to qualified third-party manufacturing partners. In parallel, we have initiated the necessary processes with the relevant authorities and other stakeholders in preparation for the sale of the manufacturing facility. We believe these actions will further streamline our operating model, reduce our fixed cost base and burn rate, and allow us to focus our resource on our core technologies and commercialization priorities. Guy will work through the specifics of the restructuring in his financial overview. We are also preparing for RS&A 2026, where we plan to engage with customers, partners, and key opinion leaders across the radiology community. RSNA provides an important platform to present our end-to-end imaging solution across NanoX ARC, NanoX AI, and our broader imaging ecosystems while supporting business development, customer engagement, and awareness of our recent commercial and clinical activity. We are preparing for RSNA 2026 with the goal of building, on last year's success in using the event as a strong commercial kickoff for 2027. I will now turn the call over to Guy, whom we are very pleased to officially welcome to the team.

Thank you, Erez. Before I begin, I would like to say that I'm very excited to be at Nanox, and I look forward to helping drive our future success as we seek to change medical imaging. As we implement the lessons we have learned and drive commercial growth, we've also sought various ways to extend our cash runway to the point where we are at a sustainable run During the quarter and subsequently, we have taken deliberate steps to implement effective measures, including reductions to our cash expenditures and cash burn. Among those steps have been a 15% headcount reduction of our Israeli-based employees, and as previously noted, a reduction in our activities at our Korean location, mainly in the chip fabrication facility, as well as an approximately 67% in our headcount in Korea. We will instead rely on our OEM partners to supply the chips we need for future demand. The estimated annualized cost savings from these steps are expected to be approximately $2 million beginning in 2027. Along with cost reductions, we also recognize the need for additional capital and have recently raised fresh capital via an existing ATM program and a registered direct offering in August that raised together a total of $8.5 million of gross proceeds. All figures that I'm reviewing now relate to the second quarter ending June 30, 2026, and all comparable figures relate to the comparable quarter of 2025, unless otherwise noted. Q2 2026 revenue were $4.2 million, compared to $3 million in Q2 2025, representing a year-over-year increase of 37%. The increase was driven mainly by the consolidation of the NanoHealth IT, formerly known as VASO Healthcare IT Business, which was consolidated as of November 19, 2025, and accounted for $0.9 million of revenue in Q2.2026. The company generated revenue of $3 million from our teleradiology services, $1 million from our AI and software solutions, and $0.2 million from the sale of imaging systems and OEM services. Q2-2026 adjusted EBDA loss, a financial measure that is derived as described below under non-GAAP financial measures, was $11.3 million, compared with adjusted EBDA loss of $10.4 million in Q2-2025. Q2-2026 gap gross loss margin was minus 1,051% compared to a gap gross loss margin of minus 107% for Q2-2025. Non-gap gross loss margin was minus 13% compared to a non-gap gross loss margin of minus 29% in Q2-2025. In accordance with applicable accounting standards, as of June 30, 2026, the company performed an impairment assessment of its asset groups. The impairment assessment was triggered by a significant decline in the company's share price and reduced forecasted revenue and operating results. The company recorded an impairment charge of $40.7 million, which was recorded to cost of revenue, impairment of intangible assets, reducing the fair value of the intangible assets related to its AI solutions business unit, excluding Nanox Health IT, to $1.9 million. The company also re-evaluated the remaining useful life of the intangible assets and concluded that no change were necessary. The impairment charge did not result in any cash outflow or impact the company's liquidity and was excluded from the calculation of the adjusted EBDA for the period. Q2-2026 gap operating expense were $11.8 million compared to gap operating expense of $11.3 million in Q2-2025. Q2-2026 non-GAAP operating expense were $11.1 million, compared to a non-GAAP operating expense of $10.0 million in Q2-2025. The increase was mainly driven by the consolidation of Nanox Health IT business and an increase in the legal expense. Q2-2026 gap net loss was $55.5 million, compared to a gap net loss of $14.7 million in Q2-2025. Q2-2026 non-gap net loss was $11.6 million, compared to a non-gap net loss of $10.9 million in Q2-2025. The increase in net loss was mainly related to the impairment of certain intangible assets as described above cash and cash equivalents and restricted deposits as of june 30 2026 were at 31.4 million this compares to a cash and cash equivalents short-term deposits and restricted deposit balance of 60 million dollars as of december 31st 2025. post-quarter end the The company raised aggregate gross proceeds of $8.5 million from its ATM program and a registered direct offering. The company intends to continue raising funds from various sources to improve its cash balance and support its activities. I'll now turn the call over to Erez for final comments and the questions and answer session.

Before we open the call for questions, I want to close by reflecting on the priorities I outline today and the progress they have produced so far we are focused on moving nanox arc systems into active use extending our commercial footprint through new partnerships advancing the nanox imaging network and adding new nanox ai customers oil while managing our resource decisively and responsibly. We made real progress across these areas by also taking the necessary steps to improve our operating structure and extend our runway. There is still plenty of work ahead, but we believe we are taking the right actions to support NANOX long-term opportunity in medical Imaging. I want to thank our employees, partners, customers, and shareholders for your continued support. Operator, you may now open the call for Q&A.

Certainly. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again.

Please stand by while we compile our Q&A roster and our first question will be coming from the line of jeffrey cohen of ladenberg thalman and company inc your line is open hey good morning just a few questions uh from our end i guess firstly for guy what's expected on the impairment for the balance of 2026 I know you're at 40.69 currently.

So currently, we already completed the process as of today, and if required, according to the accounting rules, we will continue in the future. Currently, we have no visibility for any other elements around the impairment, but we do the assessment according to the accounting rules every period, and we'll do what we need Okay, got it.

What's the latest pro forma share count? Can you repeat the question?

The latest pro forma outstanding share count?

I believe it's 70.6, if I remember correctly, million.

Got it. And then could you talk about the placements out there? I'm curious about the evaluations and the art placements. Could you give us a sense of how many were placed during the last quarter and maybe give us a sense of the pipeline that you expect throughout the balance of the year as far as placements, analysis, and evaluations.

I believe, Erez, would you like to take this answer? Yes. Would you like to answer this question?

No, I was just wondering about placements.

Can you hear me?

Now I can hear you. I'm just wondering about the outline of placements for the balance of the year.

Jeff, can you hear me?

Yes, I can.

Okay. So since the latest update, we have placed systems in Greece, in Romania, in Czech Republic. Systems for Peru are waiting for import license. Same goes with Argentina. In the U.S., we have one system which is converted from MSAS to CAPEX. We've installed another one in an IDN, another system for the first system in urgent care units in the U.S. We have three systems that are currently in the Nanox imaging network that we were talking about. one of them is already started so yeah another one in the orthopedic clinic so in a nutshell that's where we are so quite nice progress in the last quarter perfect thank you for taking the questions thank you and our next question will be coming from the line of Scott Henry of AGP Scott your line is

open.

Thank you and good morning. It sounds like there's a lot of progress going on behind the scenes as far as building momentum for future sales. Could you give us a sense of how we should think about the timing of when that traction should start? How should we think about Q3 relative to Q2 in terms of revenues, and if we're not going to see much there, when should we start to see that traction result in revenues? Thank you.

I think that we have addressed this question during the last call that we saw the middle of the year as a sort of reflection point. First of all, what you can see is the progress that you actually were talking about. And second, we will start to see the impact of this progress in the next few months, as it is previously indicated already. We view the Nanops imaging network as part of the scale which is moving forward. The business partners are, in terms of the pipeline which is being converted right now to installations or to sales, and from our point of view, The direct sales is also showing the progress. So I think that the reflection of these efforts and this momentum we will see, as we said, in the next few months.

Okay, great. So it is on track with prior expectations. Thank you. And then the $2 million in cost savings for 2027, should we expect that to show up in kind of the gross margin line or more in the G&A line?

Which one? On over?

Who are you referring to? The $2 million in cost savings on target for 2027. I just want to get a sense where in the model most of those cost savings should be located because it is in the manufacturing plant.

Yeah. So the simple answer is that probably most of the expenses would be reflected in the operating expenses, some of them in the COGS, but most of them in the OPEX.

Okay, great. And when we think about, I mean, it sounds like there are a lot of kind of cost rationalizations, getting costs out of the system, whether through contracting or what other reasons necessary. Where do you think you could get that operating expense? And that's on a gap basis. If it's been around $11 million, maybe $11 to $12 million per quarter on a gap basis, how much could you pull out of that as costs are shifted outside the system?

I try to be very cautious at this point. And if it's okay for you, I prefer not to answer this question directly. Once we have something to announce, we'll probably announce. At this point, in high level, I would say we are always doing ongoing examination and evaluation of our expenses. There is no number that I can specifically announce right now. and once the would-be number will definitely announce like we just did on the Korean side.

Okay, then I'll look forward to that. Also, in the press release, there was mention of a CMS reimbursement pathway. What would be the timing of developments on that front? Thank you.

The reimbursement of the Nanox Imaging Network? as far as through CMS the AI or the nanox imaging network both any just the timing on either how would we think about that so the the nanox the nanox AI the the geo 680 is already right now and and we see we'll probably see the the impact of it. Right now, we expect that it will be affected in the very near future, and we are going to address this segment of the market in order to benefit from this effort. In terms of the reimbursement, first of all, it's already done, so we have already uh revenues which are generated from this uh reimbursement um and uh the more systems and sites we add to the nanox imaging network which actually we've already previously indicated uh what's the uh what's the pipeline on this uh the more we'll see uh the revenues uh growing up i think that um that based on the model that we currently have and right now we are we're in the first proof of concept for this, but based on the model right now and the indications that we have from current scans that are being done on this segment of the market, we expect these numbers to be the hundreds of thousands of dollars or can go up to even more than that close to a million if the system is operating on a very wide scale, and this will generate for each one of the systems as was recorded in the press release.

Okay, great. Thank you for taking the questions.

Thank you so much.

And I'm showing no further questions. This concludes today's conference call. Thank you for participating. You may now disconnect.